The heterogeneity of intraductal carcinoma of the prostate is associated with different efficacy of standard first-line therapy for patients with metastatic castration-resistant prostate cancer.
Wang Z, Zhu S, Zhao J, Nie L, Chen X, Zhang M, Chen N, Sun G, Chen J, Ni Y, Dai J, Liu Z, Tao R, Zhang X, Zhu X, Zhang H, Liang J, Wang Z, He B, Shen P, Zeng H.
Wang Z, et al. Among authors: chen j, chen n, chen x.
Prostate. 2021 Nov;81(15):1191-1201. doi: 10.1002/pros.24215. Epub 2021 Aug 26.
Prostate. 2021.
PMID: 34435696
Free PMC article.